Congenital Myasthenic Syndromes (CMS) are a group of rare genetic disorders that affect the neuromuscular junction, leading to muscle weakness and fatigue. These syndromes are caused by mutations ...

Oppenheimer reaffirmed its positive stance on Catalyst Pharmaceutical (TADAWUL:2070) Partners (NASDAQ:CPRX), maintaining an Outperform rating and a price target of $31.00. According to InvestingPro ...

Please note that Firdapse is currently approved in the United States, the EU and Japan for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. In 2022, Catalyst ...

Congenital myasthenic syndromes (CMSs) are a heterogeneous group of disorders that affect the safety margin of neuromuscular transmission — the depolarization that is required for propagation of ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...